S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Hill-Rom Stock Forecast, Price & News

-0.08 (-0.05%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
858,524 shs
Average Volume
556,334 shs
Market Capitalization
$10.28 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive HRC News and Ratings via Email

Sign-up to receive the latest news and ratings for Hill-Rom and its competitors with MarketBeat's FREE daily newsletter.

Hill-Rom logo

About Hill-Rom

Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Year Founded

Sales & Book Value

Annual Sales
$3.02 billion
Cash Flow
$9.28 per share
Book Value
$28.46 per share


Net Income
$248.50 million
Pretax Margin




Free Float
Market Cap
$10.28 billion

Company Calendar

Dividend Payable
Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.51 out of 5 stars

Medical Sector

123rd out of 1,388 stocks

Surgical & Medical Instruments Industry

17th out of 126 stocks

Analyst Opinion: 1.1Community Rank: 4.4Dividend Strength: 3.3Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Hill-Rom (NYSE:HRC) Frequently Asked Questions

Is Hill-Rom a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hill-Rom in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Hill-Rom stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HRC, but not buy additional shares or sell existing shares.
View analyst ratings for Hill-Rom
or view top-rated stocks.

How has Hill-Rom's stock been impacted by Coronavirus?

Hill-Rom's stock was trading at $89.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HRC shares have increased by 74.6% and is now trading at $155.68.
View which stocks have been most impacted by COVID-19

Are investors shorting Hill-Rom?

Hill-Rom saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 6,570,000 shares, an increase of 23.0% from the October 31st total of 5,340,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 10.0% of the company's stock are short sold.
View Hill-Rom's Short Interest

When is Hill-Rom's next earnings date?

Hill-Rom is scheduled to release its next quarterly earnings announcement on Friday, February 4th 2022.
View our earnings forecast for Hill-Rom

How were Hill-Rom's earnings last quarter?

Hill-Rom Holdings, Inc. (NYSE:HRC) announced its earnings results on Friday, November, 5th. The medical technology company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.47 by $0.20. The medical technology company had revenue of $797.90 million for the quarter, compared to the consensus estimate of $752.97 million. Hill-Rom had a trailing twelve-month return on equity of 23.07% and a net margin of 8.23%. The company's revenue was up 13.1% compared to the same quarter last year. During the same period last year, the firm earned $1.17 earnings per share.
View Hill-Rom's earnings history

How often does Hill-Rom pay dividends? What is the dividend yield for Hill-Rom?

Hill-Rom announced a quarterly dividend on Tuesday, November 2nd. Shareholders of record on Wednesday, December 15th will be given a dividend of $0.24 per share on Friday, December 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date of this dividend is Tuesday, December 14th.
View Hill-Rom's dividend history

Is Hill-Rom a good dividend stock?

Hill-Rom pays an annual dividend of $0.96 per share and currently has a dividend yield of 0.62%. Hill-Rom has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Hill-Rom is 25.81%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Hill-Rom will have a dividend payout ratio of 13.17% next year. This indicates that Hill-Rom will be able to sustain or increase its dividend.
View Hill-Rom's dividend history.

What price target have analysts set for HRC?

6 Wall Street analysts have issued 12-month price objectives for Hill-Rom's shares. Their forecasts range from $122.00 to $156.00. On average, they expect Hill-Rom's stock price to reach $144.00 in the next twelve months. This suggests that the stock has a possible downside of 7.5%.
View analysts' price targets for Hill-Rom
or view top-rated stocks among Wall Street analysts.

Who are Hill-Rom's key executives?

Hill-Rom's management team includes the following people:
  • John P. Groetelaars, President, Chief Executive Officer & Director
  • Tim Lawrence, Senior Vice President-Operations
  • Barbara W. Bodem, Chief Financial Officer & Senior Vice President
  • Brian L. Lawrence, Chief Technology Officer & SVP-Innovation
  • Ilana Shulman, Chief Compliance Officer

What is John P. Groetelaars' approval rating as Hill-Rom's CEO?

54 employees have rated Hill-Rom CEO John P. Groetelaars on Glassdoor.com. John P. Groetelaars has an approval rating of 82% among Hill-Rom's employees.

What other stocks do shareholders of Hill-Rom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hill-Rom investors own include Steel Dynamics (STLD), Walt Disney (DIS), NVIDIA (NVDA), Square (SQ), PayPal (PYPL), salesforce.com (CRM), CVS Health (CVS), Micron Technology (MU), AbbVie (ABBV) and Bank of America (BAC).

What is Hill-Rom's stock symbol?

Hill-Rom trades on the New York Stock Exchange (NYSE) under the ticker symbol "HRC."

Who are Hill-Rom's major shareholders?

Hill-Rom's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.98%), Victory Capital Management Inc. (3.78%), Wellington Management Group LLP (3.34%), Alpine Associates Management Inc. (1.85%), Magnetar Financial LLC (1.54%) and Geode Capital Management LLC (1.26%). Company insiders that own Hill-Rom stock include Amy M Dodrill, Andreas G Frank, Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone and Paul Sherwood Johnson.
View institutional ownership trends for Hill-Rom

Which major investors are selling Hill-Rom stock?

HRC stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Victory Capital Management Inc., Fisher Asset Management LLC, Invesco Ltd., LSV Asset Management, BlackRock Inc., Neuberger Berman Group LLC, and Boston Trust Walden Corp. Company insiders that have sold Hill-Rom company stock in the last year include Deborah Rasin, Jeffrey F Dimodica, Mary Kay Ladone, and Paul Sherwood Johnson.
View insider buying and selling activity for Hill-Rom
or view top insider-selling stocks.

Which major investors are buying Hill-Rom stock?

HRC stock was acquired by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., Magnetar Financial LLC, Citigroup Inc., Capitolis Advisors LLC, Deutsche Bank AG, Versor Investments LP, Westchester Capital Management LLC, and Soros Fund Management LLC.
View insider buying and selling activity for Hill-Rom
or or view top insider-buying stocks.

How do I buy shares of Hill-Rom?

Shares of HRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hill-Rom's stock price today?

One share of HRC stock can currently be purchased for approximately $155.68.

How much money does Hill-Rom make?

Hill-Rom has a market capitalization of $10.28 billion and generates $3.02 billion in revenue each year. The medical technology company earns $248.50 million in net income (profit) each year or $3.72 on an earnings per share basis.

How many employees does Hill-Rom have?

Hill-Rom employs 10,000 workers across the globe.

What is Hill-Rom's official website?

The official website for Hill-Rom is www.hill-rom.com.

Where are Hill-Rom's headquarters?

How can I contact Hill-Rom?

Hill-Rom's mailing address is 130 East Randolph Street Suite 1000, Chicago IL, 60601. The medical technology company can be reached via phone at (312) 819-7200, via email at [email protected], or via fax at 812-934-8189.

This page was last updated on 12/5/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.